Top Markets
Coin of the day
20/20 Biolabs Inc. 20/20 Biolabs Inc.

20/20 Biolabs Inc.

AIDX
Rank in Stocks #33874
20/20 GeneSystems, Inc. operates as a clinical laboratory testing company... 20/20 GeneSystems, Inc. operates as a clinical laboratory testing company focused on cancer screening and viral testing services. The company provides multi-cancer early detection blood testing, including a test called OneTest, and offers viral testing services such as rapid COVID-19 test kits, including the Assure COVID-19 IgG/IgM rapid test. It operates the Clinical Lab Innovation Axcelerator (CLIAx), a shared laboratory facility that supports diagnostic test developers in bringing products to the U.S. market. The company also delivers its cancer screening algorithm technology through a software as a service (SaaS) platform in partnership with healthcare providers and supports diagnostic startups by offering access to shared laboratory space and resources. The company was founded in 2000 and is based in Gaithersburg, Maryland.
Share Price
$0.5475
Last synced: 2026-08-14
Market Cap
$6.71M
Change (1 day)
5.57%
Change (1 year)
-
Country
US
Trade 20/20 Biolabs Inc. (AIDX)

Category

P/B ratio for 20/20 Biolabs Inc. (AIDX)
P/B ratio as of 2026 TTM: 0
According to 20/20 Biolabs Inc. latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for 20/20 Biolabs Inc. from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors